UP421: first-in-human hypoimmune islet transplant without immunosuppression
The study behind the most-cited result in the immune-evasion field: gene-edited donor islets that survived in a person with type 1 diabetes for 12 months, and were later reported at 14 months, with no immunosuppression and no detectable anti-graft immune response. It is a two-participant, investigator-sponsored safety study, and the dose was deliberately far below a therapeutic one — the recipient stayed on insulin throughout. Survival proof, not cure proof.
Primary endpoints
- Safety, assessed by number of treatment-related adverse events (CTCAE v5.0)
Results so far
At 12 weeks and again at 6 and 12 months the graft was still producing glucose-responsive C-peptide with no immunosuppression and no detected anti-graft immune response; follow-up to 14 months was subsequently reported. The transplanted dose was roughly 2-7% of a therapeutic dose, glucose control was not an objective, and the participant remained insulin-dependent.
The full picture
The single most important immune-evasion result in type 1 diabetes so far, and one of the most frequently over-read.
What it showed. Donor islets, gene-edited so the immune system does not recognise them as foreign, were transplanted into forearm muscle in a person with long-standing type 1 diabetes — with no immunosuppression at all. The graft survived, kept producing insulin in response to glucose, and drew no detectable anti-graft immune response. Before this, essentially every islet transplant that worked required lifelong immune-suppressing drugs, whose burden is the main reason cell replacement has never been offered widely.
What it did not show. The dose was around 2-7% of a therapeutic dose — deliberately, because this is a safety study. Glucose control was not an objective and was not achieved: the participant continued taking insulin. The study has two participants and its only primary endpoint is adverse events.
Why the distinction matters. "Islets survived a year without immunosuppression" and "a cure that needs no immunosuppression" are different claims separated by roughly a 15-to-50-fold increase in cell dose — and immune evasion is not guaranteed to hold at full dose, where there is far more foreign tissue for the immune system to notice. The full-dose versions of this idea (SC451, CTX213, CNTY-813) are the ones that would actually test it, and none has produced human data.
The lesson worth carrying forward is that immune tolerance and insulin independence are separate problems. Achieving one says very little about the other, and a therapy has to clear both.